Bolt Biotherapeutics Inc.

NASDAQ: BOLT · Real-Time Price · USD
5.15
-0.29 (-5.33%)
At close: Aug 15, 2025, 3:59 PM
5.23
1.55%
After-hours: Aug 15, 2025, 04:20 PM EDT

Bolt Biotherapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
3.64M 7.69M 9.78M 11.17M 11.32M 7.88M 7.2M 6.78M 6.74M 5.73M 4.83M 3.47M 2.07M 1.26M 752K n/a 67K
Cost of Revenue
15.43M 15.89M 16.39M 16.85M 2.61M 3.33M 4M 22.52M 40.25M 40.59M 40.33M 40.69M 22.67M 21.94M 35.9M 26.11M 34.37M
Gross Profit
-11.79M -8.2M -6.61M -5.68M 8.72M 4.54M 3.19M -15.73M -33.5M -34.86M -35.5M -37.22M -20.6M -20.68M -35.15M -26.11M -34.3M
Operating Income
-68.07M -73.05M -75.9M -77.64M -74.87M -76.2M -77.47M -81.63M -84.86M -90.32M -96.36M -97.54M -98.24M -92.79M -82.64M -71.51M -58.86M
Interest Income
4.7M 5.25M 6.14M 6.8M 7.17M 7M 6.18M 4.84M 3.46M 2.22M 1.18M 724K 505K 363K 375K 268K 143K
Pretax Income
-63.35M -63.12M -65.08M -66.17M -63.03M -69.2M -71.29M -76.79M -81.4M -88.1M -95.26M -96.89M -97.81M -98.59M -102.47M -89.08M -76.55M
Net Income
-63.35M -63.12M -65.08M -66.17M -63.03M -67.76M -68.81M -74.31M -78.53M -86.46M -94.67M -96.3M -97.62M -98.59M -102.47M -89.08M -76.55M
Selling & General & Admin
16.45M 18.46M 20.04M 22M 22.75M 22.53M 22.6M 22.33M 22.24M 22.93M 22.42M 21.88M 20.4M 18.39M 15.35M 13.28M 11.23M
Research & Development
50.45M 57.01M 61.11M 62.28M 62.49M 61.05M 62.06M 66.09M 69.36M 73.12M 78.76M 79.13M 79.91M 75.66M 68.03M 58.24M 47.7M
Other Expenses
4.81M 4.81M 3.56M 3.56M n/a n/a n/a n/a n/a n/a n/a n/a n/a -6.08M -20.21M -17.83M -17.83M
Operating Expenses
67.69M 76.26M 80.7M 83.83M 85.24M 83.58M 84.67M 88.42M 91.6M 96.05M 101.18M 101M 100.31M 94.05M 83.39M 71.51M 58.93M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 82K 82K 82K 82K n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
71.71M 80.74M 85.68M 88.8M 86.2M 84.07M 84.67M 88.42M 91.6M 96.05M 101.18M 101M 100.31M 94.05M 83.39M 71.51M 58.93M
Income Tax Expense
n/a n/a n/a n/a n/a -1.44M -2.48M -2.48M -2.87M -1.64M -593K -593K -198K n/a n/a n/a n/a
Shares Outstanding (Basic)
38.34M 38.29M 38.25M 38.13M 38.07M 37.94M 37.87M 37.75M 37.68M 37.55M 37.45M 37.29M 37.13M 37.27M 37.21M 36.6M 34.22M
Shares Outstanding (Diluted)
38.34M 38.29M 38.25M 38.13M 38.07M 37.94M 37.87M 37.75M 37.68M 37.55M 37.45M 37.29M 37.13M 37.27M 37.21M 36.6M 34.22M
EPS (Basic)
-1.67 -1.66 -1.71 -1.74 -1.66 -1.79 -1.82 -1.97 -2.09 -2.31 -2.54 -2.59 -2.63 -2.71 -2.95 -3.03 -3.18
EPS (Diluted)
-1.67 -1.66 -1.71 -1.74 -1.66 -1.79 -1.82 -1.97 -2.09 -2.31 -2.54 -2.59 -2.63 -2.71 -2.95 -3.03 -3.18
EBITDA
-61.8M -66.72M -70.51M -72.23M -73.03M -74.34M -75.62M -79.81M -83.08M -88.66M -94.79M -96.11M -96.96M -91.59M -81.58M -70.59M -58.08M
EBIT
-63.53M -68.5M -72.33M -74.07M -74.87M -76.2M -77.47M -81.63M -84.86M -90.32M -96.36M -97.54M -98.24M -92.79M -82.64M -71.51M -58.86M
Depreciation & Amortization
1.72M 1.78M 1.85M 1.87M 2.61M 3.33M 4M 3.98M 3.87M 4.21M 3.95M 4.57M 4.4M 3.67M 2.99M 2.1M 1.31M